Across TCGA pan-cancer cohorts, DCAF16 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DCAF16 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher DCAF16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DCAF16 expression acts as an unfavorable survival marker.
COAD and KIRC are the cancer types where DCAF16 Mutation most reproducibly stratifies survival.